닫기
검색

PREXISE-D

Fit-for-Purpose, humice-based mAb Design & Discovery

Antibody

At the center of the development of recent breakthrough treatment modalities such as antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), bispecific antibodies (bsAbs), CAR-T, and even mRNA are monoclonal antibody (mAbs), which are often neglected due to innovative sciences spotlighting those breakthroughs.

Each treatment modality requires a unique combination of different mAb properties. Higher, but numerically lower, binding affinity is generally preferred for a ligand-receptor blockers such as ICIs but hinders applicability of the mAb to CAR-T. ADC is more complicated as it requires optimization of the target binding pattern of a mAb and the kind or the number of payloads at the final product level. A good antibody can be used for multiple applications, which is at the heart of our pipeline expansion strategy, but the wide applicability is not guaranteed — but requires PREXISE™-D, a design-driven antibody discovery platform.

We define a good antibody by its fit-for-purpose. Upon every discovery of a brand-new antibody, we exert multifactorial efforts to design the desired properties of an antibody by finding the right spot at the intersection of potentially multiple applications of the antibody. We use a humanized mice platform licensed from our global partner, and internally conduct the entire process of antibody discovery from immunization to screening by leveraging our 20-year knowhow in this field.

We aim to be the global supplier of good antibodies.